Ficlatuzumab

Ficlatuzumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	HGF
Clinical data
ATC code	none;
Identifiers
CAS Number	1174900-84-5 ;
ChemSpider	none;
UNII	77E89833TG;
KEGG	D10123 ;
Chemical and physical data
Formula	C6446H9954N1718O2026S46
Molar mass	145409.30 g·mol−1
	(what is this?)

Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.^[1]

Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with non-small cell lung cancer.^[2]

References[]

^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab" (PDF). American Medical Association.
^ "AVEO Releases Phase 2 Data", Drug Discovery & Development, dddmag.com, May 3, 2012, retrieved June 3, 2012

This monoclonal antibody–related article is a stub. You can help Wikipedia by .

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

[1] "Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab" (PDF). American Medical Association.

[2] "AVEO Releases Phase 2 Data", Drug Discovery & Development, dddmag.com, May 3, 2012, retrieved June 3, 2012

[1]

[2]